BioInsights - Optimizing mRNA purification conditions by using a high-throughput screening approach

Optimizing mRNA purification conditions by using a high-throughput screening approach

Cell & Gene Therapy Insights 2022; 8(7), 925–933

DOI: 10.18609/cgti.2022.136

Published: 29 August 2022
Jenny England

To support the development of mRNA-based therapies, Thermo Fisher Scientific has developed a platform chromatography solution for the purification of mRNA. The POROS™ Oligo (dT)25 Affinity Resin helps to address the selectivity and capacity requirements for the large-scale manufacturing of mRNA used in vaccine and gene therapy applications. Typically, mRNA binds to the Oligo (dT)25 affinity resin using high ionic strength conditions and neutral pH and is eluted from the column using low ionic strength solutions such as water. Although water works well for most mRNA constructs, a need to identify alternative elution buffers to optimize mRNA recovery exists. This article describes experiments conducted to optimize mRNA purification using high-throughput screening.